|Bid||43.85 x 1100|
|Ask||44.15 x 1200|
|Day's Range||43.83 - 44.46|
|52 Week Range||33.20 - 44.46|
|PE Ratio (TTM)||11.73|
|Earnings Date||Oct 30, 2018|
|Forward Dividend & Yield||1.36 (3.11%)|
|1y Target Est||42.39|
On September 18, Johnson & Johnson (JNJ) announced that it had submitted a new drug application to the FDA for its investigational drug, erdafitinib, for the treatment of locally advanced or metastatic UC (urothelial cancer) in patients with certain FGFR (fibroblast growth factor receptor) genetic alterations. The application is based on the findings of BLC2001, a Phase 2 study. Erdafitinib, one of the company’s key pipeline products, is expected to drive growth. The diagram below shows some of J&J’s recent pharmaceutical launches and filings expected over the next few years. In March, J&J received breakthrough therapy designation for erdafitinib from the FDA.
On September 21, Johnson & Johnson (JNJ) stock closed at $142.88, ~0.63% higher than the previous day’s closing price of $141.98. JNJ stock returned ~2.4% last week and is currently trading above its 50-day and 200-day moving averages of $135.35 and $128.52, respectively.
President Donald Trump made reducing drug prices a key promise during his election campaign, repeatedly accusing drugmakers of "getting away with murder." At the end of May, he promised that drug companies would be announcing "massive" voluntary drug price cuts within two weeks. Over the first seven months of the year, there were 96 price hikes for every price cut, the AP found. Health and Human Services Secretary Alex Azar, the administration's point person for efforts to lower drug prices, conceded in a recent AP interview that it will be a while before drug prices fall.
On September 23, Johnson & Johnson (JNJ) had a market capitalization of $376.8 billion, and its stock closed ~0.63% higher than the day prior. J&J was trading at a forward PE ratio of 16.8x, while its last-12-month PE ratio was 26.1x. Generally, a high forward PE is a sign of an overvalued or high-growth stock.
Healthcare giant Johnson & Johnson (JNJ), which has a market capitalization of $383.3 billion, submitted two new FDA drug applications this month. However, J&J continues to face litigation battles. The company has recently been asked by the Indian government to provide compensation to patients who received its faulty hip implants. In this article, we’ll look at analysts’ recommendations for JNJ stock for the next 12 months.
Dow component Pfizer Inc. ( PFE) has emerged from a multi-year period of weak performance, breaking out above 16-year resistance in the mid-$30s while setting the stage for an assault on 1999's all-time high at $49.99. No specific catalyst is driving the upside, but a deep research pipeline, dozens of partnerships and an impressive roster of profitable drugs have finally encouraged long-term skeptics to enter new positions. Given rising trade tensions, these tailwinds may continue well into the next decade, lifting Pfizer and its blue-chip peers into a series of all-time highs.
Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT(1) ...
NEW YORK, NY / ACCESSWIRE / September 24, 2018 / It was a good day for biotech stocks Pfizer and Oragenics this past Friday. While Oragenics did not have any news, the company is expected to present data ...
Zoetis is the IBD Stock Of The Day as shares of Fido's drugmaker loomed near a buy point Friday after rival Elanco Animal Health began its second day of trading.
Pfizer's (PFE) investigational pneumococcal vaccine PF-06651600 gets Breakthrough Therapy designation from the FDA for prevention of invasive disease and pneumonia.
LONDON—Some of the world’s biggest companies are drawing up plans for the unplannable: a March divorce between Britain and the European Union, in which even some basic parameters have yet to be hammered out. Big pharmaceutical firms like Pfizer Inc. and GlaxoSmithKline PLC are stockpiling medicine, on orders from the British government, just in case of long delays at the border. Cadbury maker Mondelez International Inc. is boosting supplies of chocolate and other ingredients for the same reason.
GlaxoSmithKline reported a nearly flat top line at 7.3 billion pounds, including a 4% rise in operating revenue offset by a 4% negative foreign exchange impact. GlaxoSmithKline’s business is divided into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
Pfizer Inc. (PFE) announced today that its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077, received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older.2 Pfizer expects to start Phase 3 trials in a few months.
NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to ...
In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.
—Findings from sensitivity and post-hoc analyses were presented during a Late Breaking Clinical Trials Session at the Heart Failure Society of America 22nd Annual Scientific Meetin
In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
The growing demand for AI in the health industry has encouraged IBM (IBM) to target the health sector with its Watson Health technology. The company’s increasing presence, particularly in oncology and not only in the United States but also in highly populated countries such as China and India, is also contributing to Watson Health’s growth.